Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Methamphetamine Use DisorderSubstance-Related DisordersChemically-Induced DisordersSubstance Use DisordersStimulant-Use Disorder

Interventions

DRUG

Psilocybin

25mg orally followed by 25 mg or 50 mg orally

Trial Locations (1)

University of Wisconsin, Madison

All Listed Sponsors

collaborator

Revive Therapeutics, Ltd.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER